Nyxoah Expands Belgian Manufacturing to Support U.S. and Global Growth

Event summary

  • Nyxoah is expanding its manufacturing footprint in Wallonia, Belgium, with a new 2,000 square meter facility including a state-of-the-art cleanroom.
  • The investment is part of a strategic partnership with LégiaPark and ABN Cleanroom Technology to support product development and job creation.
  • The expansion aims to meet growing demand in the U.S. and international markets for its Genio system, a leadless and battery-free neuromodulation therapy for OSA.
  • The cleanroom is designed to be scalable, allowing for future expansion as Nyxoah's manufacturing needs grow.

The big picture

Nyxoah's expansion reflects the growing demand for its Genio system, particularly in the U.S. following FDA approval in August 2025. The investment in Belgian manufacturing aligns with broader trends in the medical technology sector, where companies are increasingly focusing on localized production to enhance supply chain resilience and responsiveness to regional market needs. The strategic partnership with LégiaPark and ABN Cleanroom Technology underscores the importance of collaboration in scaling operations efficiently.

What we're watching

Execution Risk
Whether Nyxoah can successfully scale its manufacturing operations to meet increasing global demand without compromising quality or margins.
Market Dynamics
How the expansion will position Nyxoah to compete with established players in the OSA treatment market, particularly in the U.S.
Regulatory Compliance
The pace at which Nyxoah can navigate regulatory requirements in new markets while maintaining its current approvals.